加味玉屏风散联合孟鲁司特治疗儿童轻度持续性哮喘的随机安慰剂对照试验
该单中心、双盲、随机安慰剂对照试验纳入6-18岁轻度持续性哮喘患儿,比较加味玉屏风散(aYPFS)联合孟鲁司特与安慰剂联合孟鲁司特治疗24周的疗效。结果显示aYPFS组ACT™评分较基线改善最高达6.9%(p=0.016),对照组无显著改善,但其他主要和次要结局组间无显著差异。结论认为aYPFS作为孟鲁司特的附加治疗可改善哮喘控制症状,需更大样本研究进一步评估。
要点
- 加味玉屏风散联合孟鲁司特可改善轻度持续性哮喘患儿的ACT™评分。
- 肺功能等其他主要和次要结局指标组间未见显著差异。
- 两组因不良反应退出情况相当,需更大样本验证疗效与安全性。
核心结论
- 加味玉屏风散作为孟鲁司特的附加治疗可改善儿童轻度持续性哮喘的哮喘控制症状。
主要发现
- aYPFS组ACT™评分较基线改善最高达6.9%(p=0.016),对照组无显著改善。
- 其他主要和次要结局参数组间无显著差异。
- 两组因不良反应退出情况相当。
关键数值与推荐
- aYPFS组ACT™评分较基线变化最高达6.9%(p=0.016)。
临床怎么用
- 在儿童轻度持续性哮喘中,可考虑在孟鲁司特基础上加用加味玉屏风散以改善哮喘控制症状。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Traditional Chinese medicine are commonly used for treatment of asthma. However, there are only very limited data about its efficacy in children. Therefore, we aimed to determine the efficacy of augmented Yu Ping Feng San (aYPFS) as an add-on to oral montelukast compared with montelukast alone for treatment of mild persistent asthma in children. DESIGN: A single centre, placebo-controlled, double-blinded, randomized control trial was carried out. Participants with age 6-18 years who had mild persistent asthma were randomized according to random number list to receive either aYPFS plus montelukast for 24 weeks or placebo plus montelukast for 24 weeks. Primary outcome measure was lung function parameters. Secondary outcome measures were Asthma Control Test™ (ACT™) and Paediatric Allergic Disease Quality of Life Questionnaire (PADQLQ) scores, symptom-free days, short-acting β2-agonist use, use of rescue oral corticosteroids, days of hospitalization for asthma and number of emergency consultation with GPs or AED department. RESULTS: Twenty-eight participants were randomized to aYPFS group and twenty-nine to placebo group. There was no significant difference in baseline characteristics. There was significant improvement in ACT™ score in aYPFS group (up to 6.9% change from baseline) (p=0.016) but not in the control group. There were no significant differences between groups in other primary and secondary outcome parameters. Dropout because of adverse effects is comparable in both groups. CONCLUSION: Traditional Chinese medicine aYPFS as an add-on to montelukast improved symptoms of asthma control. Further studies with larger sample size are needed to evaluate its efficacy and safety in childhood asthma.
引用
- Chan PH, To CY, Chan EY, et al. A randomized placebo-controlled trial of traditional Chinese medicine as an add-on therapy to oral montelukast in the treatment of mild persistent asthma in children. Complement Ther Med. 2016. PMID: 27912950. doi:10.1016/j.ctim.2016.10.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。